Atorvastatin effect on COVID-19

Phase 2

• Conditions: Coronavirus Disease 2019 (COVID-19).; COVID-19; U07.1

• Registration Number: IRCT20190727044343N2
• Lead Sponsor: Mazandaran University of Medical Sceinces

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Confirmed COVID-19 Diagnosis
No prior Cardiovascular Disease
No history of Statins use
Chloroquine use
No prior Kaletra usage
No prior liver damage
No prior myositis

Exclusion Criteria

Prior Kaletra Use
Cardiovascular Disease
Prior myositis
Prior Liver damage

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CRP level in Blood. Timepoint: At the beginning of the study at after 5 consecutive days. Method of measurement: Blood sampling and CRP measuring.

Secondary Outcome Measures

Name	Time	Method
Mortality during the study. Timepoint: from the beginning of the study until discharge. Method of measurement: Observing.;Duration of recovery. Timepoint: From the beginning of the study until discharge. Method of measurement: Observing and case file review.